WebJun 5, 2024 · QUICK TAKE Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer 02:11. Approximately 60% of human epidermal growth factor receptor 2 … WebSep 1, 2024 · The DESTINY-Breast01 study is a clinical study in participants with a type of breast cancer called HER2-positive breast cancer. The participants in the study received a treatment called trastuzumab deruxtecan, also known as T-DXd. The purpose of this summary is to help you understand the results of the DESTINY-Breast01 study.
Trastuzumab Deruxtecan in Previously Treated HER2-Low …
WebJun 5, 2024 · DESTINY-Breast04 is a global, randomised, open-label, registrational Phase III trial evaluating the efficacy and safety of Enhertu (5.4mg/kg) versus physician’s choice … WebThe DESTINY-Breast03 study, a randomized, phase III trial pitting the antibody-drug conjugates trastuzumab emtansine and trastuzumab deruxtecan against each other in … naughty but nice wellswood torquay
Enhertu significantly improved both progression-free and overall ...
WebJul 6, 2024 · A Phase 3 trial showing positive results for a drug given to breast cancer patients who have low levels of the HER2 protein is “immediately practice-changing,” UCLA’s Sara A. Hurvitz, MD, writes in an editorial published in The New England Journal of Medicine on Wednesday. WebSep 19, 2024 · The open-label randomized DESTINY-Breast03 trial is the first global phase III head-to-head trial of T-DXd against an active control in patients with HER2-positive metastatic breast cancer following initial treatment with trastuzumab and a taxane. WebJun 5, 2024 · nejm @NEJM DESTINY-Breast04: In a phase 3 trial, trastuzumab deruxtecan resulted in longer progression-free and overall survival than the physician’s choice of … maritz research jobs